Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04731155
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2021-01-23
Brief Title:
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Sponsor:
Shanghai Tong Ren Hospital
Organization:
Shanghai Tong Ren Hospital
Study Overview
Official Title:
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PERFECT-AMI
Brief Summary:
This is a prospect multi-center random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarctionAMI can alleviate ventricular remodeling after primary percutaneous interventionPPCI Totallytwenty acute myocardium infarction subjects will be enrolled in this study after consent information After randomization the control group will receive standard therapy for AMI including PPCI The experiment group will receive first PCSK9 inhibitor before PPCI then twice a month until 3 months later Six month after AMI Myocardial salvage index will be used to evaluate ventricular remodeling TnI peaking time and LDL control rates also will be recorded and compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None